Pricing & Reimbursement

show blocks helper

Sort by Default

Display 15 Products per page

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

€2,825.10

This market analysis covers price-volume and expenditure ceilings are frequently used across Europe, payers are concerned about the budget impact of immunotherapies, price reductions are frequently required following label expansions into new populations, immunotherapy drugs present an opportunity for contracting, but payers await more competition and combination therapies pose challenges for payers as many markets do not have a clear path for HTA and price negotiation.
November 28, 2018
Find out more
HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

€2,820.39

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence
October 16, 2018
Find out more
Bladder Cancer Pricing, Reimbursement, and Access

€2,820.39

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.
September 27, 2018
Find out more
Renal Cell Cancer Pricing, Reimbursement, and Access

€2,820.39

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.
August 22, 2018
Find out more
Chronic Heart Failure Pricing, Reimbursement, and Access

€2,820.39

Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been lower than expected.
April 13, 2018
Find out more
Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

€2,820.39

Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic therapies. The market has been long dominated by the TNF-alpha inhibitors Humira and Remicade, but more recent biologic launches such as Entyvio and Stelara have focused on novel mechanisms of action.
March 16, 2018
Find out more
Ovarian Cancer Pricing, Reimbursement, and Access

€2,820.39

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascular endothelial growth factor inhibitor Avastin, followed by poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza, payers are seeing an uptick in spend for the indication.
March 5, 2018
Find out more
Latest Trends in Orphan Drug Pricing and Reimbursement

€2,820.39

It is now some 35 years since the passage of the first law designed specifically to encourage investment in the discovery and development of rare disease treatments. Activity in the sector has been transformed since then.
February 1, 2018
Find out more
Orphan Drug Access and Pricing in Emerging Markets

€2,820.39

This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized.
January 12, 2018
Find out more
Acute Myeloid Leukemia Pricing, Reimbursement, and Access

€2,820.39

The level of concern surrounding the budget impact of acute myeloid leukemia (AML) has traditionally been low due to the relatively small size of the population in comparison to solid tumors, the high severity of the disease, and a lack of branded treatment options. As a result, few access controls are utilized for AML therapies. […]
December 15, 2017
Find out more
Multiple Sclerosis Pricing, Reimbursement, and Access

€2,820.39

The multiple sclerosis (MS) market access landscape is becoming more challenging for drug manufacturers due to an increasing number of treatment modalities in the relapsing forms of MS. For the relapsing indications, payers are attempting to leverage the breadth of options by engaging in rebate contracts.
July 25, 2017
Find out more
Drug Pricing in the US

€2,820.39

Drug prices in the US have been the subject of intense debate over the past 2–3 years, following a surge in spending on prescription medicines and steep price increases in some categories
July 5, 2017
Find out more
NOACs Pricing, Reimbursement, and Access

€2,820.39

A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers.
May 10, 2017
Find out more
Rheumatoid Arthritis Pricing, Reimbursement, and Access

€2,820.39

Increased competition in the rheumatoid arthritis (RA) market resulting from biosimilar competition and the launch of me-too interleukin (IL) drugs give payers leverage to enact cost-containment measures for a drug category that has experienced high unit cost increases year over year.
April 4, 2017
Find out more
Type 2 Diabetes Pricing, Reimbursement, and Access

€2,820.39

Increased competition in the type 2 diabetes market resulting from multiple product launches in the same class and biosimilar competition is providing payers with opportunities to contain costs in the category that accounts for a significant proportion of total drug costs.
February 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *